{
  "audioUrl": "https://firebasestorage.googleapis.com/v0/b/ai-reels-873b7.firebasestorage.app/o/audio%2Fnarration-1766729505024.mp3?alt=media&token=6e63cadd-d3a6-4ffe-b646-1c93636ab045",
  "scenes": [
    {
      "contextText": "Glenmark Pharmaceuticals’ Q2 FY26 results tell a story far deeper than profit and loss. At first glance, the quarter reports a loss, but this was not caused by weak sales or slowing demand.",
      "imageUrl": "https://firebasestorage.googleapis.com/v0/b/ai-reels-873b7.firebasestorage.app/o/images%2Fscene-1766729524755.png?alt=media&token=64eb90fe-b2c3-4a3b-b236-1146baa8076f"
    },
    {
      "contextText": "The impact came from one-time exceptional charges of over ₹3,200 crore, set aside to resolve long-running U.S. antitrust lawsuits, bringing legal closure while the company continues to deny any admission of wrongdoing.",
      "imageUrl": "https://firebasestorage.googleapis.com/v0/b/ai-reels-873b7.firebasestorage.app/o/images%2Fscene-1766729531559.png?alt=media&token=893eed46-8c79-4804-9d23-05eae87acdaa"
    },
    {
      "contextText": "Operational strength remained intact, with consolidated revenue for the quarter crossing ₹60,000 crore, reflecting Glenmark’s scale across global markets.",
      "imageUrl": "https://firebasestorage.googleapis.com/v0/b/ai-reels-873b7.firebasestorage.app/o/images%2Fscene-1766729530644.png?alt=media&token=e4bde24d-8e27-409f-9785-9b5cb1978f1b"
    },
    {
      "contextText": "Then came the turning point — Glenmark’s innovation arm signed a landmark $700 million global licensing deal with AbbVie, validating its research pipeline and reshaping future cash-flow visibility.",
      "imageUrl": "https://firebasestorage.googleapis.com/v0/b/ai-reels-873b7.firebasestorage.app/o/images%2Fscene-1766729530888.png?alt=media&token=03639266-905a-4ffa-a825-f4e2c6327df7"
    },
    {
      "contextText": "Alongside this, the company restructured operations, transferred its consumer business, streamlined costs, and still declared an interim dividend of ₹2.50 per share. This quarter wasn’t about short-term profits; it was about clearing uncertainty, strengthening the core, and positioning for the next phase of growth.",
      "imageUrl": "https://firebasestorage.googleapis.com/v0/b/ai-reels-873b7.firebasestorage.app/o/images%2Fscene-1766729527791.png?alt=media&token=ffef569b-04a7-4640-a0b7-bbc46c521cf9"
    }
  ]
}